Aveanna Operating Income Jumps 56% As Corporate Costs Fall — It Raises Annual Forecasts
Sales increased 11.8%, while nine-month care costs grew faster than revenue and debt stood at $1.5 billion.
Aveanna Healthcare, which provides home nursing, hospice care and medical supplies, increased third-quarter operating income about 56% to $83.6 million as corporate costs fell 31%. The company raised its annual forecasts Thursday in an earnings release accompanying its SEC filing.
Lower Overhead Lifts Quarterly Earnings
Revenue rose 11.8% to $695.5 million from $621.9 million a year earlier. Corporate expenses declined to $35.9 million from $52.0 million, while operating income—profit before interest and taxes—rose from $53.6 million.
The quarter's gross margin, the share of sales left after direct care costs, stayed at 32.6%. Net income reached $45.5 million, compared with $14.1 million, and diluted earnings increased to $0.20 per share from $0.06.
Adjusted EBITDA, which excludes interest, taxes, depreciation and selected other costs, rose 25% to $100.1 million from $80.1 million. Its share of revenue increased to 14.4% from 12.9%. Adjusted diluted earnings were $0.23 per share, versus $0.15, after excluding acquisition costs, interest-rate derivative effects and other items.
Home Nursing Drives The Sales Increase
Private Duty Services, Aveanna's nursing and pediatric therapy business for medically complex children and young adults, contributed $59.8 million of the quarterly revenue increase. Its sales rose 11.6% to $574.2 million, and care hours increased 10.2%.
Home Health & Hospice, which mainly serves elderly patients, added $9.7 million in revenue, with sales rising 15.6% to $72.1 million. Medical Solutions, which supplies tube-feeding nutrition, equipment and respiratory-care products, added $4.1 million, bringing sales to $49.2 million, up 9.1%.
Aveanna receives reimbursement from Medicaid, Medicare, managed care organizations and commercial insurers. Across the first nine months, revenue increased 13.7%, but direct care costs grew 16.2%. Gross margin slipped to 32.3% from 33.7%, even as nine-month net income rose to $127.4 million from $46.3 million.
Higher Targets, Substantial Debt
Aveanna now expects annual revenue above $2.695 billion, compared with its previous threshold of $2.68 billion. It raised its adjusted EBITDA forecast to more than $374 million from more than $365 million.
“Given our performance through the first three quarters and confidence in our outlook, we are pleased to raise our 2026 revenue and Adjusted EBITDA guidance,” Aveanna CEO Jeff Shaner said in the release.
Operating cash flow for the first nine months reached $157.5 million, versus $76.1 million a year earlier. Free cash flow under Aveanna's measure, which accounts for capital spending, mandatory debt payments and derivative settlements, was $141.2 million.
Cash stood at $197.8 million on October 3, against $1.5 billion in debt. Nine-month interest expenses declined to $84.0 million from $107.5 million. Finance chief Matt Buckhalter said the company continues to focus on profitable growth, generating cash and reducing debt.
Aveanna is scheduled to discuss the results Thursday at 10 a.m. Eastern Time.